Tubulis - Model Topoisomerase-I -Inhibitor Platform

Our proprietary linker-payload platform offers optimized on-target delivery of potent Topoisomerase-I inhibitors combined with active reduction of unwanted target-independent toxicities. For the first time, we achieve stable and high payload attachment (DAR8) without compromising on the biophysical properties of the whole ADC molecule.

Approved Topo-I ADC using maleimide-based conjugation loses over 60 % of its payload over time resulting in an average drug-to-antibody ratio of only 3 after three days. Tubulis’ ADC using the proprietary P5 conjugation technology remains stable over seven days in serum.